Clinical Trial Update: Anti-CD19/20/22 Chimeric Antigen Receptor T Cells (TriCAR19.20.22 T Cells) for the Treatment of Relapsed or Refractory Non-Hodgkin Lymphoma, Acute Lymphoblastic Leukemia, and Chronic Lymphocytic Leukemia [Phase 1]

View source ↗

Summary

Phase 1 trial evaluating TriCAR19.20.22 T cells, a CD19/20/22-targeting CAR-T therapy, for relapsed or refractory non-Hodgkin lymphoma, acute lymphoblastic leuk…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Acute Lymphoblastic Leukemia
• Chronic Lymphocytic Leukemia
• Non-hodgkin Lymphoma

Drugs mentioned

• TriCAR19.20.22 T Cells

Snippet

Sponsor: Ohio State University Comprehensive Cancer Center | Conditions: Blast Phase Chronic Myeloid Leukemia, BCR-ABL1 Positive, Recurrent Acute Lymphoblastic Leukemia | Phase 1 | Status: RECRUITING